Vaso Corporation Appoints Shaun McMeans to Board of Directors
GlobeNewsWire
公開日時: Jul 24, 2026, 06:14 AM GMT+9
Sentiment Analysis
Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and proprietary medical products, today announced the appointment of Shaun McMeans to the Company’s Board of Directors, effective July 23, 2026.
“We are pleased to welcome Shaun to Vaso’s Board of Directors,” said Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Shaun brings substantial public company finance, accounting and operational leadership experience in the life sciences and technology sectors. We believe his background will be valuable to Vaso as we continue to execute our strategic initiatives and pursue long-term value for our stockholders.”
Mr. McMeans currently serves as Chief Financial Officer of Nabsys, a life sciences technology company, where he leads finance and administrative functions. From 2012 through 2023, Mr. McMeans served as Chief Financial Officer of HTG Molecular Diagnostics, Inc., a publicly traded life science tools and diagnostics company. Prior to joining HTG Molecular Diagnostics, Mr. McMeans held senior finance and accounting roles with Securaplane Technologies, Inc., Tatum LLC, The Long Companies, LXU Healthcare, Inc. and Burnham Holdings, Inc. Mr. McMeans received a B.S. in Accounting from The Pennsylvania State University.
About Vaso Vaso Corporation is a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and proprietary medical products. The Company operates through three principal business segments: IT, professional sales services and equipment.
Source: GlobeNewsWire
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。